Stay updated on ZPL389 Safety and Efficacy in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the ZPL389 Safety and Efficacy in Atopic Dermatitis Clinical Trial page.

Latest updates to the ZPL389 Safety and Efficacy in Atopic Dermatitis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to include new information about the drug ZPL389, specifically its dosages of 30mg and 50mg, and the revision number has been changed to v2.15.0. Significant details regarding the study design and inclusion/exclusion criteria for atopic dermatitis have been removed.SummaryDifference9%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to ZPL389 Safety and Efficacy in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ZPL389 Safety and Efficacy in Atopic Dermatitis Clinical Trial page.